| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is "too risky."
Praxis Precision Medicines recently priced its underwritten public offering of 3.17 million shares at $35.50 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 1.06 million shares at $35.4999 per pre-funded warrant, for gross proceeds of $150 million. The Boston-based company’s shares jumped around 64% over the past month.
Cramer said no to U.S. Silica Holdings, Inc. (NYSE:SLCA). During November, the Katy, Texas-based firm posted weaker-than-expected results for its third quarter.
When asked about Tetra Tech, Inc. (NASDAQ:TTEK), Cramer said, "I will bless it."
Keybanc analyst Sangita Jain recently initiated coverage on Tetra Tech with an Overweight rating and announced a price target of $191.
Don’t forget to check out our premarket coverage here
RxSight, Inc. (NASDAQ:RXST) is losing a lot of money, the "Mad Money" host said. "I want to do more work on it because they’re losing too much money for me to just say it’s fine."
RXSight recently issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
Now Read This: Tesla, American Airlines And 3 Stocks To Watch Heading Into Thursday
Image: Shutterstock
